IL122174A - DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA - Google Patents

DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA

Info

Publication number
IL122174A
IL122174A IL12217496A IL12217496A IL122174A IL 122174 A IL122174 A IL 122174A IL 12217496 A IL12217496 A IL 12217496A IL 12217496 A IL12217496 A IL 12217496A IL 122174 A IL122174 A IL 122174A
Authority
IL
Israel
Prior art keywords
cd40l
dna
leu
seq
ser
Prior art date
Application number
IL12217496A
Other languages
English (en)
Hebrew (he)
Other versions
IL122174A0 (en
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,733 external-priority patent/US5981724A/en
Priority claimed from US08/484,624 external-priority patent/US5962406A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL122174A0 publication Critical patent/IL122174A0/xx
Publication of IL122174A publication Critical patent/IL122174A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12217496A 1995-06-07 1996-06-06 DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA IL122174A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/477,733 US5981724A (en) 1991-10-25 1995-06-07 DNA encoding CD40 ligand, a cytokine that binds CD40
US08/484,624 US5962406A (en) 1991-10-25 1995-06-07 Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
PCT/US1996/009632 WO1996040918A2 (fr) 1995-06-07 1996-06-06 Muteine de cd40l

Publications (2)

Publication Number Publication Date
IL122174A0 IL122174A0 (en) 1998-04-05
IL122174A true IL122174A (en) 2004-07-25

Family

ID=27045653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12217496A IL122174A (en) 1995-06-07 1996-06-06 DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA

Country Status (15)

Country Link
EP (1) EP0832229B1 (fr)
JP (1) JP3279573B2 (fr)
KR (1) KR100453314B1 (fr)
AT (1) ATE257858T1 (fr)
AU (1) AU693713B2 (fr)
CA (1) CA2222914C (fr)
DE (1) DE69631331T2 (fr)
DK (1) DK0832229T3 (fr)
ES (1) ES2214541T3 (fr)
IL (1) IL122174A (fr)
MX (1) MX9709447A (fr)
NO (1) NO317735B1 (fr)
NZ (1) NZ311335A (fr)
PT (1) PT832229E (fr)
WO (1) WO1996040918A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
WO1998001538A1 (fr) * 1996-07-10 1998-01-15 Immunex Corporation Procede d'activation de cellules dendritiques
EP0951551B9 (fr) 1996-12-23 2012-12-26 Immunex Corporation Ligand pour l'activateur des recepteurs du nf-kappab, ligand membre de la superfamille de tnf
DE69939822D1 (de) * 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
US7494805B2 (en) 2003-02-14 2009-02-24 Biogen Idec Ma Inc. Expression cassette and vector for transient or stable expression of exogenous molecules
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
WO2005035570A2 (fr) * 2003-10-10 2005-04-21 Xencor, Inc. Nouveaux variants de la proteine cd40l
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
EP2500416A1 (fr) 2006-09-13 2012-09-19 Abbott Laboratories Améliorations de culture cellulaire
MY161866A (en) 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
EP2066339B1 (fr) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
EP2172550B1 (fr) 2007-06-29 2014-08-06 Daiichi Sankyo Company, Limited DÉRIVÉ D'ENZYME RECOMBINANTE C-TERMINAL-alpha-AMIDÉE
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3097926B1 (fr) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Compositions et procédés pour amplifier des réponses immunitaires à l'eimeria
WO2009091912A2 (fr) 2008-01-15 2009-07-23 Abbott Laboratories Vecteurs d'expression de mammifère améliorés et leurs utilisations
RS56484B1 (sr) 2009-11-17 2018-01-31 Squibb & Sons Llc Metode za poboljšanu proizvodnju proteina
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP3578190A1 (fr) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour améliorer les réactions immunitaires aux pathogènes entériques
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2017083604A1 (fr) 2015-11-12 2017-05-18 Amgen Inc. Amélioration pharmacocinétique médiée par la triazine de composés thérapeutiques
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
ES2914118T3 (es) 2016-05-11 2022-06-07 Amgen Inc Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
MX2018013762A (es) * 2016-05-13 2019-03-28 Medimmune Llc Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198025T3 (es) * 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis

Also Published As

Publication number Publication date
DE69631331D1 (de) 2004-02-19
AU6263896A (en) 1996-12-30
WO1996040918A2 (fr) 1996-12-19
CA2222914A1 (fr) 1996-12-19
DE69631331T2 (de) 2004-11-18
NO975437L (no) 1998-02-06
IL122174A0 (en) 1998-04-05
KR19990022141A (ko) 1999-03-25
MX9709447A (es) 1998-02-28
PT832229E (pt) 2004-06-30
WO1996040918A3 (fr) 1997-01-23
NO317735B1 (no) 2004-12-13
JPH11504819A (ja) 1999-05-11
KR100453314B1 (ko) 2004-12-17
ATE257858T1 (de) 2004-01-15
JP3279573B2 (ja) 2002-04-30
DK0832229T3 (da) 2004-05-03
AU693713B2 (en) 1998-07-02
NZ311335A (en) 1998-05-27
EP0832229A2 (fr) 1998-04-01
ES2214541T3 (es) 2004-09-16
EP0832229B1 (fr) 2004-01-14
NO975437D0 (no) 1997-11-26
CA2222914C (fr) 2002-04-02

Similar Documents

Publication Publication Date Title
AU693713B2 (en) CD40L mutein
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US6290972B1 (en) Method of augmenting a vaccine response by administering CD40 ligand
MXPA97009447A (en) New muteina cd
AU661360B2 (en) Novel cytokine
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
Nakamura et al. Heterodimerization of the IL-2 receptor β-and γ-chain cytoplasmic domains is required for signalling
US6165476A (en) Fusion proteins with an immunoglobulin hinge region linker
EP1229047B1 (fr) Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication
US5488032A (en) Method of using soluble human interleukin-1 receptors to suppress inflammation
US20030144182A1 (en) CD40-Ligand lacking native-pattern glycosylation
USRE35450E (en) Soluble human interleukin-1 receptors, compositions and method of use
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees